News | February 18, 2015

Radioactive Bead Therapy Now Used for Head, Neck Tumors

Holmium beads offer pinpoint radiation dispersal, can be monitored through multiple modalities

holmium beads, radiation therapy, UMC Utrecht, radiopharmaceuticals, tracers

February 18, 2015 — Researchers at University Medical Center (UMC) Utrecht are developing an innovative cancer treatment involving the injection of radioactive beads into tumors, thereby enabling a very precise localized radiotherapy. The treatment is being developed with the help of a grant from Alpe d’HuZes/Dutch Cancer Society (KWF) of nearly 300,000 euros.

Direct injection of radioactive beads may be an effective treatment of tumors that are difficult or impossible to remove surgically. This is the basic principle of medical biologist Frank Nijsen, M.D., dental surgeon Robert van Es, M.D., and nuclear physician Marnix Lam, M.D., of UMC Utrecht. They are working together with Bas van Nimwegen, M.D., of the Faculty of Veterinary Medicine of Utrecht University to treat head and neck tumors with radioactive beads.

The treatment involves holmium microspheres that appear on a magnetic resonance imaging (MRI) or a nuclear scan. Using image-guided injection, the microspheres can be inserted into a tumor in a highly precise and localized fashion. In the first three millimeters, the holmium microspheres emit 90 percent of their radiation. The treatment is radically different from similar approaches involving radioactive yttrium microspheres. Holmium microspheres can be located using MRI, computed tomography (CT) and nuclear imaging techniques. This enables improved monitoring of the holmium treatment’s safety and effectiveness.

In collaboration with the Faculty of Veterinary Medicine of Utrecht University the treatment is now being tested in pets with tumors. The preliminary results are positive. Over the past four years, 15 cats and dogs have been treated for predominantly aggressive tongue tumors. The treatment was effective in the majority of animals. On average, tumor size was reduced by 80 percent and the tongue could still be used.

“The results in these animal patients are very promising,” said Ron Koole, M.D., of the Department of Oral and Maxillofacial Surgery of UMC Utrecht. “That is why I brought together scientists working on this subject to make the treatment available to human cancer patients as well."

The grant from Alpe d’HuZes/KWF will be used by the Utrecht researchers to expand their activities in this field. This should result in a phase I clinical trial studying the safety of the treatment in cancer patients. One of the most important questions is how these microspheres should be injected in order for them to effectively spread within the tumor and produce maximum effect. Possible side effects of the treatment should also be identified.

“Head and neck tumors are of course only one application of this treatment,” says Frank Nijsen, M.D., of UMC Utrecht. “In principle, it is possible to treat any fixed tumor that can be reached with a needle with holmium microspheres. However, we first need to prove that we can inject tumors repeatedly and in a controlled manner.”

For more information: www.umcutrecht.nl

Related Content

Videos | Radiation Oncology | September 20, 2019
Anne Hubbard, MBA, director of health policy for ASTRO, explains the details and purpose of the proposed Radiation On
Videos | Radiation Therapy | September 20, 2019
ITN Associate Editor Jeff Zagoudis speaks with...
Aktina Showcases New Radiotherapy Patient Immobilization Solutions at ASTRO 2019
News | Patient Positioning Radiation Therapy | September 20, 2019
Aktina Medical introduced several new products at the 2019 American Society for Radiation Oncology (ASTRO) annual...
Varian Announces Multi-room Configuration for ProBeam 360 Proton Therapy System
News | Proton Therapy | September 20, 2019
Varian announced its ProBeam 360° proton therapy system is now available in a multi-room configuration. The ProBeam 360...
Anne Hubbard, MBA, director of health policy for the American Society for Radiation Oncology

Anne Hubbard, MBA, director of health policy for the American Society for Radiation Oncology (ASTRO), explains the details of the proposed radiation oncology alternative payment model (APM), and issues ASTRO has raised with the model, at the 2019 ASTRO annual meeting in Chicago.

News | Radiation Oncology | September 18, 2019
During its annual meeting in September, the American Society for Radiation Oncology (ASTRO) issued a response to the...
Radiation After Immunotherapy Improves Progression-free Survival for Some Metastatic Lung Cancer Patients
News | Lung Cancer | September 18, 2019
Adding precisely aimed, escalated doses of radiation after patients no longer respond to immunotherapy reinvigorates...
IBA Gathers Experts on Flash Irradiation During ASTRO
News | Proton Therapy | September 17, 2019
IBA (Ion Beam Applications SA, held its third Victoria Consortium Meeting focusing on Flash irradiation at the 2019...
Noninvasive Radioablation Offers Long-term Benefits to High-risk Heart Arrhythmia Patients
News | Radiation Therapy | September 17, 2019
September 17, 2019 — Treating high-risk heart patients with a single, high dose of...
Sun Nuclear Presents Portfolio of Independent Radiotherapy QA Solutions at ASTRO 2019

The PlanCheck module now part of SunCheck, automates plan quality checks, validates treatment plans against requirements, and automatically assesses plan performance versus intent.

News | Quality Assurance (QA) | September 16, 2019
At the 2019 American Society for Radiation Oncology (ASTRO) Annual Meeting, running Sept. 15-18 in Chicago, Sun Nuclear...
Varian Unveils Ethos Solution for Adaptive Radiation Therapy
News | Image Guided Radiation Therapy (IGRT) | September 16, 2019
At the 2019 American Society for Radiation Oncology (ASTRO) annual meeting, being held Sept. 15-18 in Chicago, Varian...